Testosterone scripts for women rise, along with denials and delays

U.S. women receiving testosterone prescriptions rose 146% from January 2023 to July 2026, but off-label users face growing pharmacy denials, dosing constraints and limited insurance coverage because no FDA-approved product exists for women. Compounded testosterone can cost roughly $100 for a three-month supply versus about $30 after discounts for a 10-month commercial-pharmacy supply. The FDA is set to review evidence for menopausal use, while more than 30 clinical trials are underway or planned, creating a potential path toward female-specific products.

Analysis

The investable issue is not current testosterone-gel revenue, which is immaterial for ABBV and retail pharmacy earnings, but the pathway from off-label fragmentation to a women-specific labeled product. An FDA workshop can clarify trial endpoints and dosing expectations over the next 1-3 months; that would lower development risk for private entrants, but an approval-grade program, safety database, and payer coverage decision still imply a 3-5 year monetization horizon. ABBV's legacy AndroGel franchise has limited upside because a formal female indication would likely require a differentiated dose/formulation rather than merely broaden demand for male-packaged gel.

AMZN's dispensing restrictions create a modest channel shift toward CVS, WMT and COST pharmacies and, more importantly, cash-pay compounders. That is not large enough to move public retail-pharmacy estimates, but it exposes a structural mismatch: controlled-substance compliance and package-level dosing constraints make scalable mail-order fulfillment less attractive until a purpose-built product exists. GDRX is a marginal loser at the transaction level because patients unable to use standard retail prescriptions or coupons migrate to compounding, where its discount economics are less applicable.

Consensus may overread rapidly rising prescription activity as proof of a near-term branded market. Much of demand is self-pay, evidence is narrow relative to the broader wellness claims, and a more explicit FDA safety posture could tighten prescriber and pharmacy behavior before it expands access. The key falsifier for the cautious view is workshop output that endorses a straightforward registrational path and a sponsor committing to a pivotal program with an approved-dose formulation; absent that, this remains a private-company development opportunity rather than a listed-equity catalyst.

Key Decisions for Investors

• No directional position in AMZN, CVS, WMT or COST on this development: even meaningful prescription rerouting is unlikely to register against pharmacy-segment revenue. Reassess only if a retailer discloses a broad controlled-substance dispensing policy that affects multiple high-volume therapies.
• Maintain ABBV as neutral on this theme; do not underwrite female-testosterone upside into valuation. A tactical positive reassessment requires evidence that ABBV is developing a female-specific formulation or licensing an asset, rather than relying on AndroGel off-label utilization.
• Set an event alert for the FDA workshop and for Marius Pharmaceuticals trial initiation/readout. If FDA feedback specifies feasible endpoints for hypoactive sexual desire disorder, screen for public contract manufacturers, specialty-pharmacy platforms, or eventual sponsor IPO exposure rather than buying broad healthcare retail.
• Avoid a short GDRX solely on coupon-denial anecdotes. The thesis becomes actionable only if quarterly data show sustained prescription-discount transaction weakness attributable to cash-pay migration; otherwise the addressable volume is too small relative to broader consumer-health and prescription-volume drivers.